Bone/Mineral Metabolism News

Serum 25-hydroxyvitamin D trajectory from childhood through early adulthood was associated with lean body mass in men and fat body mass in both men and women, according to findings from a longitudinal birth-cohort study.

Children with European ancestry are twice as likely to sustain a fracture vs. Asian children and 1.5 times more likely to experience a fracture vs. children with African ancestry, with no differences observed between boys vs. girls, according to findings published in Bone.

Eating a diet with higher proportions of red meat, potatoes, gravy and butter may increase the risk for sarcopenia in older British adults compared with a diet with more fiber, unsaturated fat spreads/oils and a higher percentage of energy from protein, according to findings published in Clinical Nutrition. 

Among menopausal women, a doubling of serum estradiol was associated with a 10% lower risk for fracture, independent of menopausal stage and level of sex hormone-binding globulin, according to an analysis of the Study of Women’s Health Across the Nation.

In older adults, a low baseline bone mineral density score and a rapid bone loss over 7 years independently conferred increased mortality risk, with a stronger association observed in men vs. women, according to findings published in Bone.

PoinT

The idea of “sunshine in a bottle” — vitamin D supplementation — has been promoted as a possible fix for everything from bone and immune system health to depression, dementia and diabetes, and the premise sells. According to recent CDC statistics, approximately 45% of middle-aged women and 38% of middle-aged men report taking a vitamin D supplement, and hundreds of thousands of Americans get tested for vitamin D deficiency each year.

Adults with type 1 diabetes and an HbA1c of at least 8% were more likely to sustain a low-trauma fracture in the 4 years after diabetes diagnosis than similar adults with an HbA1c of less than 7%, according to findings from a case-control study.

WAIKOLOA, Hawaii — Surgeons should stop bisphosphonates in patients with bisphosphonate related femur fractures at the start of treatment and treatment options may vary, according to a presenter at Orthopedics Today Hawaii.

The Bone, Reproductive and Urologic Drugs Advisory Committee of the FDA voted 18-1 Wednesday in favor of recommending approval of a biologics license application for the monoclonal antibody romosozumab for the treatment of osteoporosis in postmenopausal women at high risk for fracture, with two of 18 “yes” votes supporting a different indication for the drug.